NRIX (STOCKS)
Nurix Therapeutics, Inc. Common stock
$15.791700
-0.238300 (-1.49%)
Prev close: $16.030000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Arthur T. Sands
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,644.16M
- Employees
- 286
- P/E (TTM)
- -5.04
- P/B (TTM)
- 3.45
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
8
Strong Buy
14
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.82 | $-0.89 | +0.0680 | +7.66% |
|
Sep 2025 (Q3)
|
$-1.03 | $-0.86 | -0.1720 | -20.05% |
|
Jun 2025 (Q2)
|
$-0.52 | $-0.74 | +0.2240 | +30.11% |
|
Mar 2025 (Q1)
|
$-0.67 | $-0.78 | +0.1088 | +13.97% |
Financial Statements
| Revenues | $71.78M |
| Benefits Costs and Expenses | $272.87M |
| Costs And Expenses | $371.62M |
| Operating Expenses | $387.08M |
| Depreciation and Amortization | $8.59M |
| Research and Development | $331.38M |
| Other Operating Expenses | $51.38M |
| Operating Income/Loss | -$315.30M |
| Income/Loss From Continuing Operations After Tax | -$295.28M |
| Income/Loss From Continuing Operations Before Tax | -$201.09M |
| Income Tax Expense/Benefit | $760.00K |
| Net Income/Loss | -$295.28M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$295.28M |
| Net Income/Loss Available To Common Stockholders, Basic | -$295.28M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.17 |
| Diluted Earnings Per Share | -$3.17 |
| Basic Average Shares | 280,910,919 |
| Diluted Average Shares | 280,910,919 |
| Assets | $636.13M |
| Current Assets | $554.39M |
| Cash | $540.70M |
| Other Current Assets | $13.69M |
| Noncurrent Assets | $81.74M |
| Fixed Assets | $21.70M |
| Other Non-current Assets | $60.04M |
| Liabilities | $155.24M |
| Current Liabilities | $92.20M |
| Accounts Payable | $10.29M |
| Wages | $25.87M |
| Other Current Liabilities | $56.04M |
| Noncurrent Liabilities | $63.04M |
| Equity | $480.89M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $480.89M |
| Liabilities And Equity | $636.13M |
| Net Cash Flow From Operating Activities | -$260.29M |
| Net Cash Flow From Operating Activities, Continuing | -$260.29M |
| Net Cash Flow From Investing Activities | -$1.51M |
| Net Cash Flow From Investing Activities, Continuing | -$1.51M |
| Net Cash Flow From Financing Activities | $257.14M |
| Net Cash Flow From Financing Activities, Continuing | $257.14M |
| Net Cash Flow | -$4.65M |
| Net Cash Flow, Continuing | -$4.65M |
| Comprehensive Income/Loss | -$295.20M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$295.45M |
| Other Comprehensive Income/Loss | -$251.74M |